Abstract：
OBJECTIVE: We aimed to investigate the appropriate postoperative radiotherapy dose and selective volume in T3-4 N0 laryngeal cancer patients treated with either total or partial laryngectomy.
METHODS: Patients who received radiotherapy for locally advanced (T3-T4) and pathologic node-negative (N0) squamous cell laryngeal cancer were retrospectively evaluated. Radiotherapy was applied to median 60 Gy (range 54-60 Gy) as selective local radiotherapy (±stoma). The local treatment areas included postoperative bed + laryngeal area for patients with a partial laryngectomy, and the postoperative bed only for patients with total laryngectomy.
RESULTS: The median follow-up time was 59 months and 52 patients were included. The 2‑year, 5‑year, and 8‑year locoregional recurrence controls (LRC) were 95.6%. The 2‑year and 5‑year OS rates were 93.8% and 78.9%, respectively. The 5‑year OS for age < 60 years was 95.8%, for above 60 years 56.5%.
CONCLUSIONS: Our data suggest that local selective irradiation to the postoperative bed + stoma is enough in patients with T3-4 N0 laryngeal cancer without applying elective nodal irradiation.
METHODS: Patients who received radiotherapy for locally advanced (T3-T4) and pathologic node-negative (N0) squamous cell laryngeal cancer were retrospectively evaluated. Radiotherapy was applied to median 60 Gy (range 54-60 Gy) as selective local radiotherapy (±stoma). The local treatment areas included postoperative bed + laryngeal area for patients with a partial laryngectomy, and the postoperative bed only for patients with total laryngectomy.
RESULTS: The median follow-up time was 59 months and 52 patients were included. The 2‑year, 5‑year, and 8‑year locoregional recurrence controls (LRC) were 95.6%. The 2‑year and 5‑year OS rates were 93.8% and 78.9%, respectively. The 5‑year OS for age < 60 years was 95.8%, for above 60 years 56.5%.
CONCLUSIONS: Our data suggest that local selective irradiation to the postoperative bed + stoma is enough in patients with T3-4 N0 laryngeal cancer without applying elective nodal irradiation.
摘要：
目的：我们的目的是探讨T3-4N0喉癌患者行全喉切除术或部分喉切除术后放疗的合适剂量和选择体积。
方法：对接受局部晚期（T3-T4）和病理淋巴结阴性（N0）的鳞状细胞喉癌放疗的患者进行回顾性评估。将放射疗法应用于中位60Gy（范围54-60Gy）作为选择性局部放射疗法（±气孔）。局部治疗区域包括喉部分切除术患者的术后床+喉区，术后床只适用于全喉切除术的患者。
结果：中位随访时间为59个月，共纳入52例患者。2年,5年,8年局部区域复发控制（LRC）为95.6％。2年和5年OS率分别为93.8%和78.9%，分别。年龄<60岁的5年OS为95.8%，60年以上56.5%。
结论：我们的数据表明，对于T3-4N0喉癌患者，不应用选择性淋巴结照射，对术后床+造口进行局部选择性照射就足够了。
方法：对接受局部晚期（T3-T4）和病理淋巴结阴性（N0）的鳞状细胞喉癌放疗的患者进行回顾性评估。将放射疗法应用于中位60Gy（范围54-60Gy）作为选择性局部放射疗法（±气孔）。局部治疗区域包括喉部分切除术患者的术后床+喉区，术后床只适用于全喉切除术的患者。
结果：中位随访时间为59个月，共纳入52例患者。2年,5年,8年局部区域复发控制（LRC）为95.6％。2年和5年OS率分别为93.8%和78.9%，分别。年龄<60岁的5年OS为95.8%，60年以上56.5%。
结论：我们的数据表明，对于T3-4N0喉癌患者，不应用选择性淋巴结照射，对术后床+造口进行局部选择性照射就足够了。
